Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh
October 6, 2021 5:44 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering... More
Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement
October 4, 2021 4:05 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) files mixed shelf registration statement of:
Common Shares
Preferred Shares
Warrants
Units
Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies
October 4, 2021 11:23 AM EDTJefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel
October 4, 2021 10:39 AM EDTStifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.
The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More
